Lexaria Bioscience Corp. (LEXX)
11.18
+0.64
(+6.07%)
USD |
NASDAQ |
Aug 25, 14:33
Lexaria Bioscience EPS Diluted (Quarterly) : -1.204 for May 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2026 | -1.204 |
| February 28, 2026 | -0.8898 |
| November 30, 2025 | -1.119 |
| August 31, 2025 | -2.067 |
| May 31, 2025 | -3.106 |
| February 28, 2025 | -2.324 |
| November 30, 2024 | -2.433 |
| August 31, 2024 | -2.073 |
| May 31, 2024 | -1.929 |
| February 29, 2024 | -0.9051 |
| November 30, 2023 | -1.954 |
| May 31, 2023 | -5.523 |
| February 28, 2023 | -3.272 |
| November 30, 2022 | -4.426 |
| August 31, 2022 | -3.699 |
| May 31, 2022 | -6.006 |
| February 28, 2022 | -3.618 |
| November 30, 2021 | -5.221 |
| August 31, 2021 | -3.221 |
| May 31, 2021 | -7.514 |
| February 28, 2021 | 1.496 |
| November 30, 2020 | -3.478 |
| August 31, 2020 | -4.126 |
| May 31, 2020 | -6636.18 |
| February 29, 2020 | -160.59 |
| Date | Value |
|---|---|
| November 30, 2019 | -5.162 |
| August 31, 2019 | -6.174 |
| May 31, 2019 | -6.574 |
| February 28, 2019 | -6.664 |
| November 30, 2018 | -4.14 |
| August 31, 2018 | -7.366 |
| May 31, 2018 | -22.50 |
| February 28, 2018 | -9.00 |
| November 30, 2017 | -4.50 |
| August 31, 2017 | -4.50 |
| May 31, 2017 | -4.50 |
| February 28, 2017 | -4.50 |
| November 30, 2016 | -4.50 |
| August 31, 2016 | -4.50 |
| May 31, 2016 | -4.50 |
| February 29, 2016 | -4.50 |
| November 30, 2015 | -4.091 |
| August 31, 2015 | -5.294 |
| May 31, 2015 | -4.091 |
| February 28, 2015 | -4.091 |
| November 30, 2014 | -4.091 |
| July 31, 2014 | -1.015 |
| April 30, 2014 | -8.182 |
| January 31, 2014 | -4.091 |
| October 31, 2013 | -3.142 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Target Group, Inc. (Canada) | -0.0004 |
| InMed Pharmaceuticals, Inc. | -0.7327 |
| NervGen Pharma Corp. | -0.2283 |
| Milestone Pharmaceuticals, Inc. | -0.2063 |
| Clearmind Medicine, Inc. | -6.781 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -1.993M |
| Total Expenses (Quarterly) | 1.991M |
| Enterprise Value | 13.49M |
| Earnings Yield | -47.23% |
| Normalized Earnings Yield | -46.05 |